日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)

一项 II 期、多中心、开放标签、单臂研究，评估 berzosertib 联合拓扑替康治疗复发性铂耐药小细胞肺癌患者的疗效（DDRiver SCLC 250）。

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105918
Navarro, A; Thomas, A; Cheng, Y; Chen, Y; Reguart, N; Yoshida, T; Cousin, S; Dong, X; Yamamoto, N; Cappuzzo, F; Hallwachs, R; Bolleddula, J; Sarholz, B; Grombacher, T; Otte, M; Gounaris, I; Ferrer, J; Moulin, C; Paz-Ares, L
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
发表日期：2026
文献求助 收藏

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

综合群体药代动力学、药效学和安全性分析，为ATR抑制剂Tuvusertib的临床开发中的剂量选择提供信息

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.70029
Mukker, Jatinder Kaur; Diderichsen, Paul Matthias; Hellmann, Farina; Yap, Timothy A; Plummer, Ruth; Tolcher, Anthony W; de Bono, Johann S; Gounaris, Ioannis; Szucs, Zoltan; Zimmermann, Astrid; Kareva, Irina; Bolleddula, Jayaprakasam; Seithel-Keuth, Annick; Locatelli, Giuseppe; Enderlin, Marta; Hicking, Christine; Zutshi, Anup; Gao, Wei; Strotmann, Rainer; Benincosa, Lisa; Venkatakrishnan, Karthik
ATR
发表日期：2026
文献求助 收藏

Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective

建立对利福平介导的CYP3A诱导的生理药代动力学模型的信心：行业视角

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3477
Reddy, Micaela B; Cabalu, Tamara D; de Zwart, Loeckie; Ramsden, Diane; Dowty, Martin E; Taskar, Kunal S; Badée, Justine; Bolleddula, Jayaprakasam; Boulu, Laurent; Fu, Qiang; Kotsuma, Masakatsu; Leblanc, Alix F; Lewis, Gareth; Liang, Guiqing; Parrott, Neil; Pilla Reddy, Venkatesh; Prakash, Chandra; Shah, Kushal; Umehara, Kenichi; Mukherjee, Dwaipayan; Rehmel, Jessica; Hariparsad, Niresh
发表日期：2025
文献求助 收藏

Macrophages Transdifferentiate Into Myofibroblasts During Ocular Surface Inflammation.

眼表炎症期间巨噬细胞转分化为肌成纤维细胞

期刊:FASEB Journal
影响因子:4.2
doi:10.1096/fj.202403287RR
Sinha Nishant R, Pulimamidi Vinay K, Folorunso Olufemi S, Xi Lei, Dana Nima K, Bolleddula Jahanvi, Cho WonKyung J, Mittal Sharad K, Chauhan Sunil K
细胞生物学
巨噬细胞
炎症
发表日期：2025
文献求助 收藏

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates

建立醛氧化酶和双重醛氧化酶-CYP底物的生理药代动力学框架

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13255
Izat, Nihan; Bolleddula, Jayaprakasam; Carione, Pasquale; Huertas Valentin, Leticia; Jones, Robert S; Kulkarni, Priyanka; Moss, Darren; Peterkin, Vincent C; Tian, Dan-Dan; Treyer, Andrea; Venkatakrishnan, Karthik; Zientek, Michael A; Barber, Jill; Houston, J Brian; Galetin, Aleksandra; Scotcher, Daniel
发表日期：2025
文献求助 收藏

Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [(14)C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study

基于微量示踪剂的[(14)C]Berzosertib（一种静脉注射ATR抑制剂）在晚期实体瘤患者体内的质量平衡、药代动力学和排泄评估：一项I期研究

期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.1554
Bolleddula, Jayaprakasam; Scheible, Holger; Huber, Florian; Seithel-Keuth, Annick; Schieferstein, Hanno; Vagge, Deepthi S; Mammasse, Nadra; Jaks, Eva; Ferrer, Jordi; Moulin, Camilo; Dong, Jennifer; Venkatakrishnan, Karthik; Papai, Zsuzsanna
ATR
发表日期：2025
文献求助 收藏

Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler

以ICH E5和E17指南原则为基础，开展包容亚洲的药物研发：案例研究阐明定量临床药理学作为基础推动因素的作用

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70050
Lu, Hong; Klopp-Schulze, Lena; Mukker, Jatinder Kaur; Li, Dandan; Kuroki, Yoshihiro; Bolleddula, Jayaprakasam; Terranova, Nadia; Goteti, Kosalaram; Gao, Wei; Strotmann, Rainer; Dong, Jennifer; Venkatakrishnan, Karthik
发表日期：2024
文献求助 收藏

No person left behind: Mapping the health policy landscape for genomics research in the Caribbean

不让任何人掉队：绘制加勒比地区基因组学研究的健康政策图景

期刊:Lancet Regional Health-Americas
影响因子:7.6
doi:10.1016/j.lana.2022.100367
Bolleddula, Jyothsna; Simeon, Donald; Anderson, Simon G; Shields, Lester; Mullings, Jasneth; Ossorio, Pilar; Bethelmey, Averell; Perkins, Anna Kasafi
发表日期：2022
文献求助 收藏

Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies

利福平的替代药物：强效CYP3A诱导剂在临床药物相互作用研究中的选择综述及展望

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13357
Bolleddula, Jayaprakasam; Gopalakrishnan, Sathej; Hu, Ping; Dong, Jennifer; Venkatakrishnan, Karthik
发表日期：2022
文献求助 收藏

PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

利用生理药代动力学（PBPK）模型预测ivosidenib作为癌症患者治疗药物的药物相互作用，并验证Simcyp平台在CYP3A4诱导方面的有效性。

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12619
Bolleddula, Jayaprakasam; Ke, Alice; Yang, Hua; Prakash, Chandra
CYP3A4
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏